EE188 A Retrospective Cohort Comparing the Tuberculosis Diagnosis Related Costs and Health Resource Use (HRU) Using a Rapid Nucleic Acid Amplification (NAA) Test Vs. Conventional Tests in China, Followed By a Budget Impact Model

Full Text

1. Indirect Treatment Comparison of Pembrolizumab Versus Standard-of-Care for Relapsed and Refractory Classical Hodgkin’s Lymphoma Using Time-Varying Hazard Ratios

Abstract

Authors

E Wu S Keeping K Chan A Mojebi A Balakumaran

Back to Volume 21, Supplemental S1

1. Indirect Treatment Comparison of Pembrolizumab Versus Standard-of-Care for Relapsed and Refractory Classical Hodgkin’s Lymphoma Using Time-Varying Hazard Ratios

Abstract

Authors

ISPOR–The Professional Society for
Health Economics and Outcomes Research

Your browser is out-of-date